# Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass

> **NCT01478126** · PHASE3 · COMPLETED · sponsor: **Meshalkin Research Institute of Pathology of Circulation** · enrollment: 24 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** N(2)-L-Alanine L-Glutamine dipeptide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01478126
- **Lead sponsor:** Meshalkin Research Institute of Pathology of Circulation
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-12
- **Final completion:** 2013-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478126, "Effects of Glutamine in Ischemic Heart Disease Patients Following Cardiopulmonary Bypass". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01478126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*